Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06230367 · ClinicalTrials.gov registry record · NA

Sexual Health Advocacy for Guys - a Text Messaging-based HIV Prevention Program for Guys Who Are Into Guys

A NA study of HIV Infections, sponsored by Center for Innovative Public Health Research.

Recruiting
Registry status
NA
Development phase
5,000
Enrollment target
2
Study locations

NCT06230367 is a NA study of HIV Infections that is actively recruiting participants, run by Center for Innovative Public Health Research. The registered enrollment target is 5,000 participants, above the 437-participant average among 542 other HIV Infections trials with a reported enrollment target (1044% higher). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06230367, a NA study of HIV Infections, is actively recruiting participants, sponsored by Center for Innovative Public Health Research.

RECRUITING
Registry status
NA
Development phase
5,000 participants
Enrollment target
2
Study locations

Study Summary

SHAG is a text messaging-based HIV prevention program designed for cisgender sexual minority boys and men 13-20 years of age across the United States. Investigators will test it against a control group that receives messages about healthy lifestyle.

Conditions Studied

Interventions

  • BEHAVIORAL Sexual health advocacy for guys
  • BEHAVIORAL Healthy lifestyle control

Study Locations (2)

California

  • Center for Innovative Public Health Research - San Clemente
  • Center for Innovative Public Health Research - San Clemente

Trial Details

FieldValue
Enrollment Target 5,000 participants
Start Date 2024-01-15
Est. Completion 2026-07-31
Phase NA

What the Registry Record Tells You About NCT06230367

The ClinicalTrials.gov registry entry for NCT06230367 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 5,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 437-participant average among 542 other HIV Infections trials with a reported enrollment target (1044% higher). The listed sponsor is Center for Innovative Public Health Research, which has 8 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 2 interventions - of which Sexual health advocacy for guys is the first listed.

NCT06230367 reports 2 study locations spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT06230367 about?

NCT06230367 is a clinical study titled "Sexual Health Advocacy for Guys - a Text Messaging-based HIV Prevention Program for Guys Who Are Into Guys". SHAG is a text messaging-based HIV prevention program designed for cisgender sexual minority boys and men 13-20 years of age across the United States. Investigators will test it against a control group that receives messages about healthy lifestyle.

What is the current status of trial NCT06230367?

This trial is currently recruiting. It is a NA study. The enrollment target is 5,000 participants. The study started on 2024-01-15. Estimated completion is 2026-07-31.

What conditions does trial NCT06230367 study?

This clinical trial studies the following conditions: HIV Infections.

What interventions are being tested in trial NCT06230367?

The interventions under investigation include: Sexual health advocacy for guys (BEHAVIORAL), Healthy lifestyle control (BEHAVIORAL).

Who is sponsoring clinical trial NCT06230367?

This trial is sponsored by Center for Innovative Public Health Research, which has 8 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06230367 being conducted?

This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.